MX2016012722A - Metodos para tratar el virus de la hepatitis c. - Google Patents
Metodos para tratar el virus de la hepatitis c.Info
- Publication number
- MX2016012722A MX2016012722A MX2016012722A MX2016012722A MX2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- weeks
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención caracteriza terapias libres de interferón para el tratamiento del VHC. Preferiblemente, el tratamiento es sobre una duración más corta de tratamiento, tal como no más de 12 semanas. En un aspecto, el tratamiento comprende administrar al menos dos agentes antivíricos de acción directa y ribavirina a un sujeto con la infección del VHC, en donde el tratamiento tiene una duración de 12 semanas y no incluye administración de interferón, y al menos los dos agentes antiviricos de acción directa comprenden (a) Compuesto 1 o una sal farmacéuticamente aceptable del mismo y (b) Compuesto 2 o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461973930P | 2014-04-02 | 2014-04-02 | |
US201461989953P | 2014-05-07 | 2014-05-07 | |
US201462016460P | 2014-06-24 | 2014-06-24 | |
PCT/US2015/023922 WO2015153792A1 (en) | 2014-04-02 | 2015-04-01 | Methods for treating hcv |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016012722A true MX2016012722A (es) | 2016-12-16 |
Family
ID=52875323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016012722A MX2016012722A (es) | 2014-04-02 | 2015-04-01 | Metodos para tratar el virus de la hepatitis c. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160317603A9 (es) |
EP (1) | EP3125890A1 (es) |
JP (2) | JP6559701B2 (es) |
CN (1) | CN106456621A (es) |
AU (2) | AU2015240753B2 (es) |
CA (1) | CA2943054A1 (es) |
MX (1) | MX2016012722A (es) |
WO (1) | WO2015153792A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
BR112016022976A8 (pt) | 2014-04-02 | 2021-07-20 | Abbvie Inc | métodos para o tratamento de hcv |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
WO2019074507A1 (en) * | 2017-10-12 | 2019-04-18 | Abbvie Inc. | METHODS FOR THE TREATMENT OF HCV |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003900553A0 (en) * | 2003-02-10 | 2003-02-20 | Borody, Thomas Julius | Novel Improved Method for Detection of Dientamoeba fragilis and other Parasites |
US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US9394279B2 (en) * | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
MX343275B (es) * | 2010-09-21 | 2016-10-31 | Enanta Pharm Inc | Prolina macrociclica derivada de inhibidores de serina proteasa de vhc. |
US20140080869A1 (en) * | 2012-09-18 | 2014-03-20 | Abbvie Inc. | Methods for Treating HCV |
MX367796B (es) * | 2012-09-18 | 2019-09-06 | Abbvie Inc | Usos médicos para tratar hepatitis c. |
PT2968302T (pt) * | 2013-03-14 | 2018-01-03 | Abbvie Inc | Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc |
KR102210935B1 (ko) * | 2013-03-14 | 2021-02-02 | 애브비 인코포레이티드 | C형 간염 치료용 2가지 항바이러스제의 병용물 |
BR112016022976A8 (pt) * | 2014-04-02 | 2021-07-20 | Abbvie Inc | métodos para o tratamento de hcv |
-
2015
- 2015-04-01 WO PCT/US2015/023922 patent/WO2015153792A1/en active Application Filing
- 2015-04-01 MX MX2016012722A patent/MX2016012722A/es unknown
- 2015-04-01 CN CN201580029196.XA patent/CN106456621A/zh active Pending
- 2015-04-01 JP JP2016560558A patent/JP6559701B2/ja not_active Expired - Fee Related
- 2015-04-01 AU AU2015240753A patent/AU2015240753B2/en not_active Ceased
- 2015-04-01 US US14/676,378 patent/US20160317603A9/en not_active Abandoned
- 2015-04-01 EP EP15716681.0A patent/EP3125890A1/en not_active Withdrawn
- 2015-04-01 CA CA2943054A patent/CA2943054A1/en not_active Abandoned
-
2019
- 2019-07-18 JP JP2019132501A patent/JP2019214578A/ja active Pending
-
2020
- 2020-04-16 AU AU2020202560A patent/AU2020202560A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP6559701B2 (ja) | 2019-08-14 |
CN106456621A8 (zh) | 2017-07-04 |
AU2020202560A1 (en) | 2020-05-07 |
EP3125890A1 (en) | 2017-02-08 |
CN106456621A (zh) | 2017-02-22 |
JP2017509674A (ja) | 2017-04-06 |
WO2015153792A1 (en) | 2015-10-08 |
US20160317603A9 (en) | 2016-11-03 |
CA2943054A1 (en) | 2015-10-08 |
JP2019214578A (ja) | 2019-12-19 |
US20150283199A1 (en) | 2015-10-08 |
AU2015240753A1 (en) | 2016-09-29 |
AU2015240753B2 (en) | 2020-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
MX2020005054A (es) | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. | |
MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
MX2018000240A (es) | Metodos para tratar el vhc. | |
PH12018550201A1 (en) | Hepatitis b antiviral agents | |
PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
MX2018010805A (es) | Agentes antivirales contra la hepatitis b. | |
PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
MX2015017953A (es) | Metodos para tratar el virus de hepatitis c. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
MX2020001422A (es) | Metodos para el tratamiento de hcv. | |
MX2018001905A (es) | Metodos para el tratamiento del virus de hepatitis c (vhc). | |
AU2019384793A8 (en) | Methods for treating acute HCV | |
MX2018000213A (es) | Metodos para tratar el vhc. | |
NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
UA101772U (uk) | Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки | |
UA104615U (uk) | Спосіб лікування токсокарозу | |
ES2572355A2 (es) | Combinacion de aad para uso en el tratamiento del vhc | |
RU2012121337A (ru) | Способ лечения животных при ассоциативных инфекционных болезнях различной этиологии |